- Scrip Originals
- Featured Topics
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Par Pharmaceuticals
After a COVID-19-led manufacturing halt at its India facility and a slowdown in US launches hit Strides during the first quarter of FY22, the Indian firm is trying to fight back with an acquisition of assets from Endo and a growth strategy for Stelis Biopharma’s vaccines business, led by Sputnik V.